Theravance’s First NDA Is Antibiotic Telavancin

Firm is seeking approval of telavancin for complicated skin and skin structure infections caused by Gram-positive bacteria.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet